Molecular epidemiology: Cancer risk assessment using biomarkers for detecting early health effects in individuals exposed to occupational and environmental carcinogens

Reviews on Environmental Health

Volumn 12, Issue 3, 1997, Pages 179-190

  Indulski, Janusz A ^a   Lutz, Waldemar ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CARCINOGENESIS; DOSE RESPONSE; DOSIMETRY; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION; GENE MUTATION; MOLECULAR BIOLOGY; OCCUPATIONAL EXPOSURE; ONCOGENE; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

EID: 0030704244     PISSN: 00487554     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVEH.1997.12.3.179     Document Type: Article

References (61)

1. World Health Organization. Biomarkers and Risk Assessment: Concepts and Principles. Environmental Health Criteria 155. Geneva: WHO, 1993.
2. Brandt-Rauf PW. The molecular epidemiology of oncoproteins. Scand J. Work Environ Health 1992; 18: 46-49.
3. Brandt-Rauf PW, Smith SJ, Perera FP. Molecular epidemiology and environmental carcinogenesis of the lung. Probl Respir Care 1990; 3: 44-61.
4. Markham AF, Coletta PL, Robinson PA, et al. Screening for cancer predisposition. Eur J Cancer 1994; 30A: 2015-2029.
5. McMahon G. The genetics of human cancer: Implications for ecotoxicology. Environ Health Perspect 1994; 102: 75-80.
6. Rhodes N, Paules RS, Roberts JD. Molecular mechanisms of environmental carcinogencsis. Environ Health Perspect 1995; 103: 504-506.
7. Shaham J, Ribak J. The role of biomarkers in detecting early changes relating to exposure to occupational carcinogens. J Occup Health 1996; 38: 170-178.
8. Sorsa M. Genetic monitoring: Experiences, possibilities, and applications in occupational health practices. Int J Occup Environ Health 1996; 2: 554-556.
9. Ward JB, Henderson RE. Identification of needs in biomarker research. Environ Health Perspect 1996; 104: 895-900.
10. Brandt-Rauf PW. Oncogenes and their applications in epidemiological studies. Am J Epidemiol 1990; 131: 1099-1100.
11. Brandt-Rauf PW. Oncogenes and oncoproteins in occupational carcinogensis. Scand J Work Environ Health 1992; 18: 27-30.
12. Hennings H, Glick AB, Greenhalgh DA, et al. Critical aspects of initiation, promotion and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med 1993; 202: 1-8.
13. Indulski JA, Lutz W. Biomarkers used for assessment of cancer risk in populations living in areas of high potential carcinogenic hazard (near communal and chemical waste dumping sites). In: Subramanian KS, Iyengar GV, eds, Environmental Biomonitoring. Exposure Assessment and Specimen Banking. Washington, DC: American Chem Soc, 1997; 195-205.
14. Groopman JD, Sabbioni G, Wild D. Molecular dosimetry of human aflatoxin exposures. In Groopman JD, Skipper PL, eds, Molecular Dosimetry and Human Cancer - Analytical, Epidemiological and Social Considerations. Boca Raton, FL: CRC Press, 1991; 303-324.
15. Tornqvist M, Landin HH. Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation. J Occup Environ Med 1995; 37:1077-1084.
16. Vogelstein B, Kinzler KW. Carcinogens leave fingerrints. Nature 1992; 355: 209-210.
17. Eubanks M. Biomarkers: The clues to genetic susceptibility. Environ Health Perspect 1994; 102: 50-56.
18. Shuker D, Prevost V, Friesen MD, et al. Urinary markers for measuring exposure to endogenous and exogenous alkylating agents and precursors. Environ Health Perspect 1993; 99: 33-37.
19. Hemminki K, Randerath K, Reddy MV, et al. Post-abeling of immunoassay of polycyclic aromatic hydrocarbons adducts of deoxyribonucleic acid in white blood cells of foundry workers. Scand J Work Environ Health 1990; 16: 158-162.
20. Vineis P, Caporaso N, Tannenbaum SR, et al. Acetylation phenotype, carcinogen-hemoglobin adducts and cigarette smoking. Cancer Res 1990; 50: 3002-3004.
21. 1guanine adducts and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res 1987; 47: 3430-3433.
22. Shaham J, Bomstein Y, Melzer A, et al. DNA-protein crosslinks, a biomarker of exposure to formaldehyde in vitro and in vivo studies. Carcinogenesis 1996; 17: 121-125.
23. Stolley PD, Soper KA, Galloway SM, et al. Sister chromatid exchange in association with occupational exposure to ethylene oxide. Mutat Res 1984; 129: 89-112.
24. Brandt-Rauf PW. New markers for monitoring occupational cancer: The example of oncogene proteins. J Occup Med 1988; 30: 399-404.
25. Cooper GM. Oncogenes as markers for early detection of cancer. J Cell Biochem 1992; Suppl 16G: 131-136.
26. Diamandis EP. Oncogenes and tumor suppressor genes: New biochemical testes. Crit Rev Clin Lab Sci 1992; 29: 269-305.
27. Fontanini G, Fiore L, Bigini D, et al. Levels of p53 antigen in the serum of non-small lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement. Int J Oncol 1994; 5: 553-558.
28. Kratzke RA. Shimizu E. Kaye FJ. Oncogenes in human lung cancer. Cancer Treat Res 1992; 63: 61-85.
29. Weissfeld JL, Larsen RD, Niman HL, et al. Evaluation of oncogene-related proteins in serum. Cancer Epidemiol Biomarkers Prev 1994; 3: 57-62.
30. Winter Sf, Minna JD, Johnson BE, et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168-4174.
31. Laurent C. SCE increases after an accidental acute inhalation exposure to ETO and recovery to normal after 2 years. Mutat Res 1988; 204: 711-717.
32. Sarto F, Tornqvist MA, Tomanin R, et al. Studies of biological and chemical monitoring of low-level exposure to ethylene oxide. Scand J Environ Health 1991; 119: 60-64.
33. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637.
34. Evans HJ, Prosser J. Tumor-supressor genes: Cardinal factors in inherited predisposition to human cancers, Environ Health Perspect 1992; 98: 25-37.
35. Lane DP. p53 and human cancers. Br Med Bull 1994; 50: 582-599.
36. Marion MJ, Froment O, Trepo C. Activation of K-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinogenesis 1991; 4: 450-454.
37. Taylor JA, Li Y, He M, et al. p53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res 1996; 55: 294-298.
38. Taylor JA, Watson MA, Devereux TR, et al. p53 mutation hot spot in radon-associated lung cancer. Lancet 1994; 343: 86-87.
39. Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations in p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992; 339: 675-679.
40. Brandt-Rauf PW, Niman HL, Smith SJ. Correlation between oncogene protein expression and the development of neoplastic disease in workers exposed to carcinogens. J R Soc Med 1990; 83: 594-595.
41. Lutz W, Sulkowski W, Krajewska B. Oncoproteins as biomarkers of preclinical form of cancer of the respiratory tract induced by environmental carcinogens. Pol J Occup Med Environ Health 1993; 6: 347-355.
42. 53 alteration in human cancer: A review. Int J Cancer 1994; 57: 1-9.
43. Brandt-Rauf PW, Smith SJ, Niman HL, et al. Serum oncogene proteins in foundry workers. J Soc Occup Med 1990; 40: 11-14.
44. Ford J, Smith S, Luo JC, et al. Serum growth factors and oncoproteins in firelighters. Occup Med 1992; 42: 39-42.
45. Brandt-Rauf PW, Niman HL. Serum screening for oncogene proteins in workers exposed to PCBs. Br J Ind Med 1988; 45: 689-695.
46. Brandt-Rauf PW, Smith S, Hemminki K, et al. Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 1992; 50: 881-885.
47. Hemminki K, Partanen R, Koskinen H, et al. The molecular epidemiology of oncoproteins. Serum p53 protein in patients with asbestosis. Chest 1996; 109: 22S-28S.
48. Lubin R, Schlichholz B, Teillaud JL, et al. p53 antibodies in patients with various types of cancer: Assay, identification and characterization. Clin Cancer Res 1995; 1: 1463-1469.
49. Trivers GE, De Bendette VMG, Cawley HL. et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996; 2: 1767-1775
50. Daly AK, Cholerton S, Armstrong M, et al. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994; 102: 55-61.
51. Wolf CR, Smith CAD, Gough AC, et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992; 13: 1035-1038.
52. Daly AK, Armstrong M, Monkman SC, et al. The genetic and metabolic criteria for assignment of debrisoquine hydroxylation (cytochrome P450IID6) phenotypes. Pharmacogenetics 1991; 1: 33-41.
53. Board P, Coggan M, Johnston P, et al. Genetic heterogeneity of the human glutathione transferase: A complex of gene families. Pharmacol Therap 1990; 48: 357-369.
54. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and acetyltransferase phenotype in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
55. Hickman D, Sim E. N-acetyltransferase polymorphism: Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42: 1007-1014.
56. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 1990; 263: 131-133.
57. Shimada T, Yun C-H, Hiroshi Y, et al. Characterization of human lung microsomal cytochrome P-4501A1 and its role in the oxidation of chemical carcinogens Mol Pharmacol 1992; 41: 856-864.
58. Vineis P, D'Errico A. Genetic susceptibility to chemical-induced cancers: Methodologic problems. Int J Occup Environ Health 1996; 2: 550-553.
59. Oesch F, Aulmann W. Platt KL, et al. Individual differences in DNA repair capacities in man. Arch Toxicol 1987; 10: 172-179.
60. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination and cancer biology. Annu Rev Biochem 1996; 65: 101-133.
61. Lynch H T, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 1996; 78: 1149-1167.